End Cash (Annual)

End Cash: The amount of cash held by the company for the given period.

Lexicon Pharmaceuticals, Inc. (LXRX) had End Cash of $63.33M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$49.80M
Net Income	$-50.34M
Cost of Goods Sold	$0.27M
Gross Profit	$49.53M
Operating Expenses	$98.71M
Operating Income	$-48.91M
Non-Operating Income/Expense	$-1.43M
Pre-Tax Income	$-50.34M
Normalized Pre-Tax Income	$-50.34M
Income after Taxes	$-50.34M
Income from Continuous Operations	$-50.34M
Consolidated Net Income/Loss	$-50.34M
Normalized Income after Taxes	$-50.34M
EBIT	$-48.91M
EBITDA	$-46.59M
Weighted-Average Shares Outstanding (Basic)	363.05M
Weighted-Average Shares Outstanding (Diluted)	363.05M
Earnings per Share (EPS) (Basic)	$-0.14
Earnings per Share (EPS) (Diluted)	$-0.14
Balance Sheet Financials
Current Assets	$101.89M
Property, Plant, and Equipment	$1.86M
Long-Term Assets	$83.09M
Total Assets	$184.99M
Current Liabilities	$20.87M
Long-Term Debt	$49.41M
Long-Term Liabilities	$56.58M
Total Liabilities	$77.45M
Common Equity	$107.54M
Tangible Shareholders Equity	$62.99M
Shareholders Equity	$107.54M
Common Shares Outstanding	365.85M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-67.85M
Cash Flow from Investing Activities	$113.02M
Cash Flow from Financial Activities	$-48.50M
Beginning Cash	$66.66M
End Cash	$63.33M
Increase/Decrease in Cash	$-3.33M
Stock-Based Compensation	$12.52M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.88
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.31
Debt to Equity Ratio	0.50
Gross Margin	99.45%
Operating Margin	-98.21%
EBIT Margin	-98.21%
EBITDA Margin	-93.55%
Pre-Tax Profit Margin	-101.08%
Profit Margin	-101.08%
Free Cash Flow	$-67.85M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.27
Inventory Turnover	0.98
Receiveable Turnover	20.89
Days Sales in Receivables	17.47
Return on Equity	-46.81%
Return on Tangible Equity	-79.91%
Return on Assets	-27.21%
Return on Investments	-32.08%
Book Value Per Share	$0.29
Free Cash Flow per Share	$-0.19
Operating Cash Flow per Share	$-0.19

Data from Zacks Investment Research, Inc.